Provectus' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at 10th European Association of Dermato-Oncology Congress
Monday April 21, 2014
Presentation Scheduled for Wednesday, May 7, 2014, in Vilnius Lithuania KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), announced today that Dr. Sanjiv Agarwala of St. Luke's University Health Network will present clinical data on Provectus' PV-10 preparation for the treatment of melanoma at the 10th European Association of Dermato-Oncology (EADO) Congress in Vilnius, Lithuania. The Congress runs from May 7-10, 2014, and Dr. Agarwala's presentation is scheduled for the first day of the Congress, Wednesday, May 7.
Dr. Craig Dees, PhD, CEO of Provectus, said, "Provectus is happy to see our colleague Dr. Agarwala sharing what he and his team at St. Luke's have learned about PV-10 in the treatment of melanoma with the members of EADO at this year's Congress."
PV-10, a 10% solution of Rose Bengal that is currently being examined as a novel cancer therapeutic, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, minimizing potential for systemic side effects.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140421 on the Provectus website. |
